Last updated on April 24, 2014 at 1:21 EDT

Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer

April 2, 2012

QUÉBEC CITY, April 2, 2012 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the “Company”) today announced that the Phase 3
“X-PECT” (Xeloda® + Perifosine Evaluation in Colorectal cancer
Treatment) clinical trial evaluating perifosine + capecitabine
(Xeloda®) in patients with refractory advanced colorectal cancer did
not meet the primary endpoint of improving overall survival versus
capecitabine + placebo. The trial involving 468 patients in 65 sites in
the U.S was conducted by the Company’s North American licensee partner,
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX).

Juergen Engel, Ph.D., Aeterna Zentaris President and Chief Executive
Officer, commented, “Although we are obviously very disappointed that
the trial did not meet its primary endpoint, I would like to thank all
those involved in this trial for their dedicated work. We are currently
conducting further data analyses in collaboration with our licensee
partners, in order to determine the future development strategy for
perifosine. Our other ongoing late-stage programs with AEZS-108 and
AEZS-130, as well as earlier-stage programs from our deep pipeline will
continue as planned, with a sufficient cash position to pursue these
programs for more than the next 12 months.”

The Company will host a conference call and webcast later today, Monday,
April 2, 2012 at 10:00 a.m. (Eastern). Participants may access the live
webcast through the Company’s website at www.aezsinc.com in the “Newsroom” section, or by telephone: in Canada, (514) 807-9895
or (647) 427-7450, outside Canada, (888) 231-8191. A replay of the
webcast will also be available on the Company’s website for a period of
15 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company
currently investigating potential treatments for various cancers. The
Company’s innovative approach of “personalized medicine” means
tailoring treatments to a patient’s specific condition and to unmet
medical needs. Aeterna Zentaris’ deep pipeline is drawn from its
proprietary discovery unit providing the Company with constant and
long-term access to state-of-the-art therapeutic options. For more
information please visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to
the safe harbour provisions of the U.S. Securities Litigation Reform
Act of 1995. Forward-looking statements involve known and unknown risks
and uncertainties that could cause the Company’s actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the risk that safety and efficacy data
from any of our Phase 3 trials may not coincide with the data analyses
from previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to take advantage of business opportunities in
the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. Investors should
consult the Company’s quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The Company
does not undertake to update these forward-looking statements. We
disclaim any obligation to update any such factors or to publicly
announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, unless required to do so by a governmental authority or
by applicable law.


Source: PR Newswire